Delving into the Latest Updates on Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (Toyouvax) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Multivalent vaccine

Synonyms

Quadrivalent Influenza Vaccine (Toyouvax), 四价流感病毒裂解疫苗（MDCK细胞）（浙江天元）

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza, Human

Inactive Indication-

Originator Organization

Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

Active Organization

Northwest Minzu University

Lanzhou Bailing Biotechnology Co., Ltd.

Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (08 Jul 2025),

Influenza, Human

Regulation-

Login to view timeline

主要目的：四价流感病毒裂解疫苗（MDCK细胞）在6月龄及以上健康人群中接种的安全性。次要目的：四价流感病毒裂解疫苗（MDCK细胞）在6月龄及以上健康人群中接种的免疫原性。探索性目的：探索3~8岁人群以2种免疫程序接种四价流感病毒裂解疫苗（MDCK细胞）的免疫原性。

[Translation]

Primary objective: Safety of quadrivalent influenza virus split vaccine (MDCK cells) in healthy people aged 6 months and above. Secondary objective: Immunogenicity of quadrivalent influenza virus split vaccine (MDCK cells) in healthy people aged 6 months and above. Exploratory objective: Explore the immunogenicity of quadrivalent influenza virus split vaccine (MDCK cells) in 2 immunization schedules in people aged 3 to 8 years.

Start Date30 Mar 2024

Sponsor / Collaborator

Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

[+2]

CTRI/2022/07/044219

/ CompletedNot ApplicableIIT

Evaluation of efficacy and safety of Quadrivalent Influenza Vaccine (FluQuadri TM) in patients with Inflammatory Bowel Disease (IBD) â?? a case-control proof of concept study

Start Date01 Aug 2022

Sponsor / Collaborator-

CTR20221439

/ CompletedPhase 3

四价流感病毒裂解疫苗（成人规格）在中国 3 岁及以上健康人群中进行的单中心、随机、双盲、同类制品平行对照Ⅲ期临床试验

[Translation] A single-center, randomized, double-blind, parallel-controlled phase III clinical trial of quadrivalent influenza virus split vaccine (adult specification) in healthy people aged 3 years and above in China

主要目的：评价试验疫苗在 3 周岁及以上人群中接种的免疫原性。次要目的：评价试验疫苗在 3 周岁及以上人群中接种的安全性。

[Translation]

Primary objective: To evaluate the immunogenicity of the trial vaccine in people aged 3 years and above. Secondary objective: To evaluate the safety of the trial vaccine in people aged 3 years and above.

Start Date10 May 2022

Sponsor / Collaborator

Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

100 Clinical Results associated with Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (Toyouvax)

Login to view more data

100 Translational Medicine associated with Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (Toyouvax)

Login to view more data

100 Patents (Medical) associated with Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (Toyouvax)

Login to view more data

100 Deals associated with Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (Toyouvax)

Login to view more data